# The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease

> **NCT07457125** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Xuanwu Hospital, Beijing** · enrollment: 33 (estimated)

## Conditions studied

- Mild to Moderate Alzheimer's Disease

## Interventions

- **DRUG:** Exosomes derived from umbilical cord mesenchymal stem cell for intranasal drop
- **DRUG:** A placebo of exosomes derived from umbilical cord mesenchymal stem cell for intranasal drop

## Key facts

- **NCT ID:** NCT07457125
- **Lead sponsor:** Xuanwu Hospital, Beijing
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-10
- **Primary completion:** 2028-12-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-03-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07457125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07457125, "The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07457125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*